TEGRETOL-XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tegretol-xr, and when can generic versions of Tegretol-xr launch?
Tegretol-xr is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in TEGRETOL-XR is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tegretol-xr
A generic version of TEGRETOL-XR was approved as carbamazepine by TARO on October 3rd, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TEGRETOL-XR?
- What are the global sales for TEGRETOL-XR?
- What is Average Wholesale Price for TEGRETOL-XR?
Summary for TEGRETOL-XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 163 |
| Clinical Trials: | 25 |
| Patent Applications: | 4,294 |
| Drug Prices: | Drug price information for TEGRETOL-XR |
| Drug Sales Revenues: | Drug sales revenues for TEGRETOL-XR |
| DailyMed Link: | TEGRETOL-XR at DailyMed |
See drug prices for TEGRETOL-XR
Paragraph IV (Patent) Challenges for TEGRETOL-XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TEGRETOL-XR | Extended-release Tablets | carbamazepine | 100 mg | 020234 | 1 | 2005-12-30 |
US Patents and Regulatory Information for TEGRETOL-XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-001 | Mar 25, 1996 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-002 | Mar 25, 1996 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-003 | Mar 25, 1996 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEGRETOL-XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-002 | Mar 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-001 | Mar 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-003 | Mar 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | TEGRETOL-XR | carbamazepine | TABLET, EXTENDED RELEASE;ORAL | 020234-002 | Mar 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEGRETOL-XR
See the table below for patents covering TEGRETOL-XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 194780 | ⤷ Sign Up | |
| Sweden | 502590 | Oralt terapeutiskt system innehållande karbamazepin med systemisk verkan, förfarande för framställning och användning därav | ⤷ Sign Up |
| Hong Kong | 33793 | ORAL SUSTAINED RELEASE FORMS OF CARBAMAZEPINE | ⤷ Sign Up |
| Spain | 2007100 | PROCEDIMIENTO PARA LA OBTENCION DE UN SISTEMA TERAPEUTICO ORAL A BASE DE CARBAMAZEPINA. (Oral therapeutic system having systemic action) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
